Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000439795

Medchemexpress LLC D-α-Hydroxyglutaric acid | 13095-47-1 | 98.0% | 148.11 | 1 ML
SDP

Catalog No. 5000439795
Encompass_Preferred

D-α-Hydroxyglutaric acid is the primary metabolite that accumulates in the neurometabolic disorder D-2-hydroxyglutaric aciduria. It acts as a weak competitive antagonist of α-ketoglutarate (α-KG), inhibiting multiple α-KG-dependent dioxygenases with a Ki of 10.87 mM. This compound increases reactive oxygen species (ROS) production, binds to and inhibits ATP synthase, and suppresses mTOR signaling. It also accumulates in human cancers with neomorphic mutations in IDH1 and IDH2 genes.

  • Weak competitive antagonist of α-ketoglutarate (α-KG).
  • Inhibits multiple α-KG-dependent dioxygenases.
  • Increases reactive oxygen species (ROS) production.
  • Binds to and inhibits ATP synthase.
  • Suppresses mTOR signaling.
  • Accumulates in human cancers with IDH1 and IDH2 gene mutations.

Catalog No. 50-004-39795 Supplier Medchemexpress LLC Supplier No. HY11303810MM/1ML
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

D-α-Hydroxyglutaric acid is the primary metabolite that accumulates in the neurometabolic disorder D-2-hydroxyglutaric aciduria. It acts as a weak competitive antagonist of α-ketoglutarate (α-KG), inhibiting multiple α-KG-dependent dioxygenases with a Ki of 10.87 mM. This compound increases reactive oxygen species (ROS) production, binds to and inhibits ATP synthase, and suppresses mTOR signaling. It also accumulates in human cancers with neomorphic mutations in IDH1 and IDH2 genes.

  • Weak competitive antagonist of α-ketoglutarate (α-KG).
  • Inhibits multiple α-KG-dependent dioxygenases.
  • Increases reactive oxygen species (ROS) production.
  • Binds to and inhibits ATP synthase.
  • Suppresses mTOR signaling.
  • Accumulates in human cancers with IDH1 and IDH2 gene mutations.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.